Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of BTK Inhibitor DTRMWXHS-12 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

NCT03836768 is registered in ClinicalTrials.gov with Zhejiang DTRM Biopharma as lead sponsor.

NCT NCT03836768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03836768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of BTK Inhibitor DTRMWXHS-12 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Lead sponsor
Zhejiang DTRM Biopharma
Phase
Phase 1
Overall status
Completed
Start date
January 11, 2019
Completion date
November 17, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma